Echo Street Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Echo Street Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,129	Closed	-$811K	–	556
2023 Q2	$811K	Buy	1,129 +693	+159%	+$534K	0.01%	175
2023 Q1	$358K	Sell	436 -174	-29%	-$131K	﹤0.01%	344
2022 Q4	$440K	Buy	+610	New	+$450K	﹤0.01%	315
2022 Q3	–	Sell	-467	Closed	-$276K	–	675
2022 Q2	$276K	Buy	+467	New	+$304K	﹤0.01%	445
2022 Q1	–	Sell	-1,284	Closed	-$811K	–	720
2021 Q4	$811K	Buy	1,284 +828	+182%	+$509K	0.01%	295
2021 Q3	$276K	Sell	456 -349	-43%	-$217K	﹤0.01%	531
2021 Q2	$450K	Sell	805 -244	-23%	-$124K	﹤0.01%	399
2021 Q1	$496K	Buy	1,049 +284	+37%	+$138K	﹤0.01%	298
2020 Q4	$370K	Buy	+765	New	+$413K	﹤0.01%	296
2020 Q3	–	Sell	-627	Closed	-$391K	–	318
2020 Q2	$391K	Buy	+627	New	+$356K	﹤0.01%	374

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Echo Street Capital Management's REGN Position: Q3 2023 in Review

Echo Street Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 1,129 shares — an estimated $811K sold.

Echo Street Capital Management first reported a position in REGN in Q2 2020 and held it in 10 quarters. The position peaked at $811K in Q2 2023. 1,178 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

Echo Street Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Echo Street Capital Management sold 1,129 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $811K.
Echo Street Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 10 quarters.
Echo Street Capital Management's Regeneron Pharmaceuticals position peaked at $811K in Q2 2023.
1,178 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Echo Street Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.